Immatics

72 articles about Immatics

• immatics biotechnologies GmbH Raises EUR54 Million ($71 Million) to Advance its Late Stage Clinical Therapeutic Cancer Vaccine Portfolio

  9/21/2010

• Scancell Enters Research Collaboration With immatics biotechnologies GmbH To Develop Novel Immunobody(R) Vaccines For Colorectal Cancer

  6/29/2010

• immatics biotechnologies GmbH Significantly Improves XPRESIDENT(TM) Technology Platform

  6/17/2009

• immatics biotechnologies GmbH Completes Patient Recruitment In Phase II Study With Cancer Vaccine IMA901 For Renal Cell Cancer

  3/3/2009

• immatics biotechnologies GmbH Wins 29th German Industry's Innovation Award

  1/26/2009

• immatics biotechnologies GmbH Obtains Important U.S. and European Patents

  7/14/2008

• immatics biotechnologies GmbH Appoints Paul G. Higham as Chief Executive Officer

  7/9/2008

• immatics biotechnologies GmbH Receives 3 Research Grants Totaling 1.4 mn € to Advance its Early-Stage Cancer Immunotherapy Programs

  7/7/2008

• immatics biotechnologies GmbH Granted Orphan Drug Status for Therapeutic Cancer Vaccine IMA901

  3/14/2007

• immatics biotechnologies GmbH Receives 40 Million Eur In Second Round Of Cancer Treatment Funding

  2/8/2007

• immatics biotechnologies GmbH Succesfully Concludes Phase 1 Clinical Study On Potential Renal Cell Cancer Vaccine

  10/10/2006

• immatics biotechnologies GmbH And responsif GmbH Sign A Cooperation Agreement Within The Scope Of The BioChancePLUS Grant Program

  5/22/2006